Cargando…
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells
Small interfering RNA (siRNA) therapies require effective delivery vehicles capable of carrying the siRNA cargo into target cells. To achieve tumor-targeting, a drug delivery system would have to incorporate ligands that specifically bind to receptors expressed on cancer cells to function as portals...
Autores principales: | Camorani, Simona, Tortorella, Silvia, Agnello, Lisa, Spanu, Chiara, d’Argenio, Annachiara, Nilo, Roberto, Zannetti, Antonella, Locatelli, Erica, Fedele, Monica, Comes Franchini, Mauro, Cerchia, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609037/ https://www.ncbi.nlm.nih.gov/pubmed/36297659 http://dx.doi.org/10.3390/pharmaceutics14102225 |
Ejemplares similares
-
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
por: Agnello, Lisa, et al.
Publicado: (2021) -
Optimization of Short RNA Aptamers for TNBC Cell Targeting
por: Camorani, Simona, et al.
Publicado: (2022) -
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023) -
Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells
por: Agnello, Lisa, et al.
Publicado: (2023) -
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
por: Camorani, Simona, et al.
Publicado: (2018)